The Food and Drug Administration (FDA) approved today a new drug to treat adult and pediatric patients aged 12 years and older with Homozygous Familial Hypercholesterolemia (HoFH), the rare and most severe form of FH.This is welcome news, as individuals with HoFH usually are not able to adequately … Read More →
Author Archives: Cat Davis Ahmed
The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have … Read More →
the Family Heart Foundation started 2021 off with an impactful Listening Session with the Food and Drug Administration (FDA) Center for Drug Evaluation and Research Division of Diabetes, Lipid Disorders, and Obesity (DDLO) on Homozygous Familial Hypercholesterolemia (HoFH) on January 4. Kate Robinson … Read More →
If you have Familial Hypercholesterolemia (FH) or if you have atherosclerotic cardiovascular disease (ASCVD), or both, please take some time to fill out this questionnaire about living with High Cholesterol for the Institute for Clinical and Economic Review (ICER).
Sharing your experience can make a … Read More →
the Family Heart Foundation is pleased to report that the first-ever FH Advocacy Group in Iraq was launched on May 22, 2020. Ms. Fatima Lahmood, a strong FH warrior living with Familial Hypercholesterolemia (FH) and a pharmacy student, has taken on the leadership role as patient representative, working … Read More →
On January 28, 2020, the Family Heart Foundation and some of our amazing community members and leaders, who are FH Advocates for Awareness, will go to Capitol Hill to ask our elected representatives for their continued support in prioritizing familial hypercholesterolemia (FH) as a public health concern … Read More →
the Family Heart Foundation is a true partnership of individuals and families impacted by FH, and the healthcare professionals who diagnose and treat FH. Together, we are raising awareness of FH, driving improved diagnosis, making sure individuals know their treatment options and opportunities for … Read More →
Affordable prescription drugs are necessary so individuals can benefit from advances in medicine to treat conditions such as familial hypercholesterolemia. Medical research and innovation make it possible to actually prevent or delay heart disease in people born with FH. All it takes is early diagnosis … Read More →
Ask the Pharmacy – Are you getting the lowest cost for your PCSK9 inhibitor?
The manufacturers of both PCSK9 inhibitors, Praluent and Repatha, have lowered the list price for these cholesterol-lowering treatments by 60% to $5,850 per year. As we reported in February, the Family Heart Foundation … Read More →
the Family Heart Foundation welcomes Sanofi and Regeneron’s announcement today to lower the list price of its LDL cholesterol lowering treatment, the PCSK9 inhibitor Praluent, to $5,850 annually. This brings the list price of Praluent in line with Amgen’s PCSK9 inhibitor, Repatha, which was … Read More →